Publication: Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: Effects on leptin and TNF-alpha.
dc.contributor.author | Montes de Oca-Arjona, M | |
dc.contributor.author | Pérez-Cano, R | |
dc.contributor.author | Garcia-Juárez, R | |
dc.contributor.author | Martín-Aspas, A | |
dc.contributor.author | Fernández-Gutiérrez del Alamo, C | |
dc.contributor.author | Girón-González, J A | |
dc.contributor.authoraffiliation | [Montes de Oca-Arjona, M; Pérez-Cano, R; García-Juarez, R; Martín-Aspas, A; Girón-Gonzáez, JA] Internal Medicine Services, Hospital Universitario Puerta del Mar, Cádiz, Spain. [Fernández-Gutiérrez del Álamo, C] Microbiology Services, Hospital Universitario Puerta del Mar, Cádiz, Spain. | es |
dc.date.accessioned | 2012-12-10T10:22:49Z | |
dc.date.available | 2012-12-10T10:22:49Z | |
dc.date.issued | 2006-04 | |
dc.description | This is a copy of an article published in the AIDS Research and Human Retroviruses © 2011 [copyright Mary Ann Liebert, Inc.]; AIDS Research and Human Retroviruses is available online at: http://online.liebertpub.com. Comparative Study; Journal Article; | es |
dc.description.abstract | The changes in nutritional parameters and adipocytokines after structured intermittent interruption of highly active antiretroviral treatment of patients with chronic HIV infection are analyzed. Twenty-seven patients with chronic HIV infection (median CD4+ T cell count/microl: nadir, 394; at the beginning of structured interruptions, 1041; HIV viral load: nadir, 41,521 copies/ml; at the beginning of structured interruptions <50 copies/ml; median time of previous treatment: 60 months) were evaluated during three cycles of intermittent interruptions of therapy (8 weeks on/4 weeks off). CD4+ T cell count, HIV viral load, anthropometric measures, and serum concentrations of triglycerides, cholesterol, leptin, and tumor necrosis factor and its soluble receptors I and II were determined. After the three cycles of intermittent interruptions of therapy, no significant differences in CD4+ T cell count/microl, viral load, or serum concentrations of cholesterol or triglycerides with reference to baseline values were found. A near-significant higher fatty mass (skinfold thicknesses, at the end, 121 mm, at the beginning, 100 mm, p = 0.100), combined with a significant increase of concentration of leptin (1.5 vs. 4.7 ng/ml, p = 0,044), as well as a decrease in serum concentrations of soluble receptors of tumor necrosis factor (TNFRI, 104 vs. 73 pg/ml, p = 0.022; TNFRII 253 vs. 195 pg/ml, p = 0.098) were detected. Structured intermittent interruption of highly active antiretroviral treatment of patients with chronic HIV infection induces a valuable positive modification in markers of lipid turnover and adipose tissue mass. | es |
dc.description.version | Yes | es |
dc.identifier.citation | Montes de Oca-Arjona M, Pérez-Cano R, Garcia-Juárez R, Martín-Aspas A, Fernández-Gutiérrez del Alamo C, Girón-González JA. Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: effects on leptin and TNF-alpha. AIDS Res. Hum. Retroviruses. 2006 ; 22(4):307-14 | es |
dc.identifier.doi | 10.1089/aid.2006.22.307 | |
dc.identifier.essn | 1931-8405 | |
dc.identifier.issn | 0889-2229 | |
dc.identifier.pmid | 16623632 | |
dc.identifier.uri | http://hdl.handle.net/10668/696 | |
dc.journal.title | AIDS research and human retroviruses | |
dc.language.iso | en | |
dc.publisher | Mary Ann Liebert Inc | es |
dc.relation.publisherversion | http://online.liebertpub.com/doi/abs/10.1089/aid.2006.22.307 | es |
dc.rights.accessRights | open access | |
dc.subject | RNA, Viral | es |
dc.subject | Receptors, Leptin | es |
dc.subject | Receptors, Tumor Necrosis Factor, Type I | es |
dc.subject | Receptors, Tumor Necrosis Factor, Type II | es |
dc.subject | Triglycerides | es |
dc.subject | Tumor Necrosis Factor-alpha | es |
dc.subject | Leptin receptor, human | es |
dc.subject | Cholesterol | es |
dc.subject | Leptin | es |
dc.subject | ARN Viral | es |
dc.subject | Receptores Tipo I de Factores de Necrosis Tumoral | es |
dc.subject | Receptores de Leptina | es |
dc.subject | Receptores Tipo II del Factor de Necrosis Tumoral | es |
dc.subject | Triglicéridos | es |
dc.subject | Factor de Necrosis Tumoral alfa | es |
dc.subject | Leptina | es |
dc.subject | Colesterol | es |
dc.subject | Receptores de leptina, humanos | es |
dc.subject | Recuento de Linfocito CD4 | es |
dc.subject | Estudios de Casos y Controles | es |
dc.subject | Linfocitos T CD4-Positivos | es |
dc.subject | Enfermedad crónica | es |
dc.subject | Grosor de Pliegues Cutáneo | es |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy, Combination::Antiretroviral Therapy, Highly Active | es |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Clinical Laboratory Techniques::Cytological Techniques::Cell Count::Blood Cell Count::Leukocyte Count::Lymphocyte Count::CD4 Lymphocyte Count | es |
dc.subject.mesh | Medical Subject Headings::Anatomy::Hemic and Immune Systems::Blood::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes::CD4-Positive T-Lymphocytes | es |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Cholestanes::Cholestenes::Cholesterol | es |
dc.subject.mesh | Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease | es |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Administration Schedule | es |
dc.subject.mesh | Medical Subject Headings::Check Tags::Female | es |
dc.subject.mesh | Medical Subject Headings::Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections | es |
dc.subject.mesh | Medical Subject Headings::Organisms::Viruses::RNA Viruses::Retroviridae::Lentivirus::Lentiviruses, Primate::HIV::HIV-1 | es |
dc.subject.mesh | Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Peptide Hormones::Adipokines::Leptin | es |
dc.subject.mesh | Medical Subject Headings::Check Tags::Male | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Viral | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Adipokine::Receptors, Leptin | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Cytokine::Receptors, Tumor Necrosis Factor::Receptors, Tumor Necrosis Factor, Type II | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Biological Factors::Antigens::Antigens, Surface::Antigens, Differentiation::Antigens, CD::Receptors, Tumor Necrosis Factor, Type II | es |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Weights and Measures::Reference Standards | es |
dc.subject.mesh | Medical Subject Headings::Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Skinfold Thickness | es |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Lipids::Glycerides::Triglycerides | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Tumor Necrosis Factors::Tumor Necrosis Factor-alpha | es |
dc.subject.mesh | Medical Subject Headings::Phenomena and Processes::Microbiological Phenomena::Virus Physiological Phenomena::Viral Load | es |
dc.subject.mesh | Medical Subject Headings::Named Groups::Persons::Age Groups::Adult | es |
dc.title | Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: Effects on leptin and TNF-alpha. | es |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- MontesdeOca_StructuredIntermittent.pdf
- Size:
- 181.96 KB
- Format:
- Adobe Portable Document Format
- Description:
- Artículo publicado